Clinical trial

Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients

NCT01131364

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2008-06-01

PhasePHASE1 / PHASE2

Study timeline

Study start (unknown)2008-06-01Date precision: month

Registry last updated2014-02-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Solid Tumorunresolved

Breast Cancerunresolved

Interventions

F16IL2 in combination with doxorubicinDRUG

Sponsors & collaborators

Philogen S.p.A.lead sponsor

Mapped research locations

MilanItaly1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01131364 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.